Sunday, 18 May 2025
  
Login

Australia's most trusted
source of pharma news

Sunday, 18 May 2025
News

PBS win sparks new revenue battle

Posted 29 July 2024 PM

A new PBS expansion for a blockbuster could see it challenge for the position of top most reimbursed drug - again.

Vertex scored the expansion for cystic fibrosis drug Trikafta to extend the eligible age from six years and above to two years and above, in patients who have at least one F508del mutation on the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

To see the whole article, please login

Popular

Company in trouble with the FDA
June PBS listings ready to roll
Govt quietly funds Novartis drug
No crash despite patent cliff fall
Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (1)

Sales & Customer Relations (12)

Clinical & Medical, R&D (6)

Regulatory, Pharmacovigilance & QA (4)

Devices (1)

Other (14)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home